TP53 and myelodysplastic syndrome: Clinical evaluation of APR-246 in p53 mutant myelodysplastic syndromes (MDS) revealed a dramatic 82% rate of complete response, leading to a fast track designation and an orphan drug designation of APR-246 by Food and Drug Administration (FDA) in April 2019 [19,20].